AR060120A1 - Medio y metodo para diagnosticar la diabetes - Google Patents
Medio y metodo para diagnosticar la diabetesInfo
- Publication number
- AR060120A1 AR060120A1 ARP070101229A ARP070101229A AR060120A1 AR 060120 A1 AR060120 A1 AR 060120A1 AR P070101229 A ARP070101229 A AR P070101229A AR P070101229 A ARP070101229 A AR P070101229A AR 060120 A1 AR060120 A1 AR 060120A1
- Authority
- AR
- Argentina
- Prior art keywords
- diabetes
- predisposition
- metabolite
- acid
- metabolites
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 9
- 238000000034 method Methods 0.000 title abstract 4
- 239000002207 metabolite Substances 0.000 abstract 10
- REIUXOLGHVXAEO-UHFFFAOYSA-N pentadecan-1-ol Chemical compound CCCCCCCCCCCCCCCO REIUXOLGHVXAEO-UHFFFAOYSA-N 0.000 abstract 2
- XEZVDURJDFGERA-UHFFFAOYSA-N tricosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(O)=O XEZVDURJDFGERA-UHFFFAOYSA-N 0.000 abstract 2
- BITHHVVYSMSWAG-KTKRTIGZSA-N (11Z)-icos-11-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCC(O)=O BITHHVVYSMSWAG-KTKRTIGZSA-N 0.000 abstract 1
- MPCAJMNYNOGXPB-SLPGGIOYSA-N 1,5-anhydro-D-glucitol Chemical compound OC[C@H]1OC[C@H](O)[C@@H](O)[C@@H]1O MPCAJMNYNOGXPB-SLPGGIOYSA-N 0.000 abstract 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 abstract 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 abstract 1
- QXKAIJAYHKCRRA-BXXZVTAOSA-N D-ribonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O QXKAIJAYHKCRRA-BXXZVTAOSA-N 0.000 abstract 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 abstract 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 abstract 1
- 235000000431 campesterol Nutrition 0.000 abstract 1
- 238000013500 data storage Methods 0.000 abstract 1
- 229940108623 eicosenoic acid Drugs 0.000 abstract 1
- BITHHVVYSMSWAG-UHFFFAOYSA-N eicosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCC(O)=O BITHHVVYSMSWAG-UHFFFAOYSA-N 0.000 abstract 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 abstract 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract 1
- 239000011976 maleic acid Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
- Y10T436/144444—Glucose
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Endocrinology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un método para diagnosticar la diabetes o una predisposicion a ésta que comprende determinar por lo menos un metabolito en una muestra de ensayo de un sujeto sospechado de sufrir diabetes o de tener una predisposicion a ésta y comparar dicho por lo menos un metabolito con una referencia, por la cual la diabetes o una predisposicion a ésta debe diagnosticarse. Un conjunto de metabolitos, un conjunto de datos que comprenden valores característicos de los metabolitos y un medio de almacenamiento que comprende dicho conjunto de datos. Además, un sistema que comprende medios para comparar valores característicos de los metabolitos de una muestra ligada en forma funcional a un medio de almacenamiento de datos. Adicionalmente, medios de diagnostico que comprenden por lo menos un metabolito y el uso de dicho por lo menos un metabolito para la fabricacion de medios de diagnostico para diagnosticar la diabetes. Finalmente, un método para identificar metabolitos relacionados con la diabetes. Reivindicacion 1: Un método para diagnosticar la diabetes o una predisposicion a ésta caracterizado porque comprende: (a) determinar por lo menos un metabolito en una muestra de ensayo de un sujeto sospechado de sufrir diabetes o de tener una predisposicion a ésta, dicho por lo menos un metabolito se selecciona del grupo formado por: 1,5-anhidrosorbitol, ácido eicosenoico (C20:1), eritrol, ácido ribonico, ácido tricosanoico (C23:0), pentadecanol, campesterol, ácido maleico y ácido melísico (C30:0); y (b) comparar los resultados de las pruebas de la determinacion del paso (a) con una referencia, por la cual la diabetes o una predisposicion a ésta debe diagnosticarse.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06111705A EP1837657A1 (en) | 2006-03-24 | 2006-03-24 | Means and method for predicting or diagnosing diabetes |
| EP06120273 | 2006-09-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR060120A1 true AR060120A1 (es) | 2008-05-28 |
Family
ID=38016918
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070101230A AR060121A1 (es) | 2006-03-24 | 2007-03-23 | Medio y metodo para predecir la diabetes |
| ARP070101229A AR060120A1 (es) | 2006-03-24 | 2007-03-23 | Medio y metodo para diagnosticar la diabetes |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070101230A AR060121A1 (es) | 2006-03-24 | 2007-03-23 | Medio y metodo para predecir la diabetes |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8216848B2 (es) |
| EP (6) | EP2005189B1 (es) |
| JP (4) | JP5199994B2 (es) |
| CN (1) | CN101438168B (es) |
| AR (2) | AR060121A1 (es) |
| AT (2) | ATE493660T1 (es) |
| CA (2) | CA2647122A1 (es) |
| DE (2) | DE602007011592D1 (es) |
| ES (4) | ES2522815T3 (es) |
| WO (2) | WO2007110358A2 (es) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2647122A1 (en) * | 2006-03-24 | 2007-10-04 | Metanomics Gmbh | Means and method for diagnosing diabetes |
| EP2164977B1 (en) | 2007-07-17 | 2013-10-30 | Metabolon, Inc. | Biomarkers for pre-diabetes and methods using the same |
| EP2209001A4 (en) * | 2007-10-25 | 2010-10-27 | Ajinomoto Kk | METHOD FOR ASSESSING STROKEN GLUCOSE TOLERANCE |
| US8658427B2 (en) | 2008-05-28 | 2014-02-25 | Basf Se | Means and methods for assessing increased peroxisomal proliferation |
| DE112009001245T5 (de) * | 2008-05-28 | 2012-03-15 | Basf Se | Mittel und Verfahren für die Beurteilung der Leberenzyminduktion |
| DE112009001234T5 (de) | 2008-05-28 | 2011-04-28 | Basf Se | Mittel und Verfahren zur Abschätzung von Lebertoxizität |
| US20110113863A1 (en) * | 2008-07-15 | 2011-05-19 | Metanomics Health Gmbh | Means and methods diagnosing gastric bypass and conditions related thereto |
| DE102009013914B4 (de) * | 2009-03-19 | 2011-05-05 | Bruker Daltonik Gmbh | Kalibriersubstanzen für Atmosphärendruck-Ionenquellen |
| EP2411812B1 (en) | 2009-03-24 | 2013-10-02 | AnaMar AB | Metabolic profiles |
| EP2804001B1 (en) * | 2009-06-04 | 2017-08-09 | Metanomics Health GmbH | Methods for diagnosing prostate carcinomas |
| WO2011018288A1 (en) * | 2009-08-13 | 2011-02-17 | Basf Se | Means and methods for diagnosingthyroid disorders |
| US8367359B1 (en) * | 2009-10-23 | 2013-02-05 | The United States Of America, As Represented By The Secretary Of Agriculture | Metabolic biomarkers for diabetes and insulin resistance |
| ES2728120T3 (es) * | 2010-01-29 | 2019-10-22 | Metanomics Gmbh | Medios y procedimientos para diagnosticar insuficiencia cardíaca en un sujeto |
| US20130126725A1 (en) * | 2010-07-30 | 2013-05-23 | Technische Universität Graz | Analyses of Analytes by Mass Spectrometry with Values in at Least 3 Dimensions |
| WO2012051463A2 (en) * | 2010-10-14 | 2012-04-19 | The Regents Of The University Of California | Urine metabolomic profile of diabetic kidney disease |
| EP2656074A4 (en) * | 2010-12-23 | 2014-10-29 | Metanomics Health Gmbh | MEDIUM AND METHOD FOR PREDICTING DIABETES |
| US20130101984A1 (en) * | 2011-10-20 | 2013-04-25 | The Washington University | Methods of detecting sleepiness |
| US20150044702A1 (en) * | 2012-03-09 | 2015-02-12 | Basf Se | Means and methods for assessing disorders related to impaired iron adsorption or energy metabolism |
| US9361429B2 (en) | 2012-06-08 | 2016-06-07 | Liposcience, Inc. | Multi-parameter diabetes risk evaluations |
| US9470771B2 (en) | 2012-06-08 | 2016-10-18 | Liposcience, Inc. | NMR measurements of NMR biomarker GlycA |
| US9928345B2 (en) | 2012-06-08 | 2018-03-27 | Liposciences, Inc. | Multiple-marker risk parameters predictive of conversion to diabetes |
| EP2867669B1 (en) | 2012-06-27 | 2016-12-21 | Metanomics Health GmbH | Methods for identifying diabetes drugs |
| EP2909626B1 (en) | 2012-10-18 | 2018-07-04 | metanomics GmbH | Means and methods for determining a clearance normalized amount of a metabolite disease biomarker in a sample |
| US9910047B2 (en) * | 2013-01-31 | 2018-03-06 | Metabolon, Inc. | Biomarkers related to insulin resistance progression and methods using the same |
| KR102362357B1 (ko) * | 2013-04-09 | 2022-02-15 | 아지노모토 가부시키가이샤 | 생활습관병 지표의 평가 방법, 생활습관병 지표 평가 장치, 생활습관병 지표 평가 방법, 생활습관병 지표 평가 프로그램, 생활습관병 지표 평가 시스템, 및 정보통신 단말장치 |
| CN103616465A (zh) * | 2013-10-28 | 2014-03-05 | 浙江大学 | 血液相关脂肪酸谱的建立方法 |
| US20150323520A1 (en) * | 2014-05-07 | 2015-11-12 | The Trustees Of The Stevens Institute Of Technology | Diagnosis of kidney transplant acute rejection |
| JP6773951B2 (ja) * | 2014-05-30 | 2020-10-21 | 学校法人東京医科大学 | 唾液試料の調製方法 |
| US11255866B2 (en) * | 2015-02-26 | 2022-02-22 | Wisconsin Alumni Research Foundation | Methods for predicting glucoregulatory dysfunction via diacylglycerol fatty acid species concentrations |
| KR20170002318A (ko) * | 2015-06-29 | 2017-01-06 | 고려대학교 산학협력단 | 대사체 분석을 이용한 당뇨병 조기 진단용 조성물 |
| CN106979982B (zh) * | 2016-01-19 | 2021-01-05 | 上海市第六人民医院 | 一种用于糖尿病风险预测、治疗评价的方法及试剂盒 |
| CN105699663A (zh) * | 2016-04-06 | 2016-06-22 | 深圳市老年医学研究所 | 2型糖尿病唾液蛋白指纹图谱分子诊断模型建立方法 |
| CN105784829A (zh) * | 2016-04-06 | 2016-07-20 | 深圳市老年医学研究所 | 2型糖尿病肾虚证唾液蛋白指纹图谱分子诊断模型建立方法 |
| US20190271708A1 (en) * | 2016-05-17 | 2019-09-05 | Osaka University | Blood sample analysis method and system, for determining diabetes |
| EP3602605A4 (en) * | 2017-03-31 | 2020-12-30 | Metabolon, Inc. | FULL AND QUANTITATIVE ANALYSIS OF LIPIDS AND TOCOPHEROLS |
| EP3669192B1 (en) * | 2017-08-17 | 2021-06-30 | Société des Produits Nestlé S.A. | Use of a kit of parts for measuring markers in prepuberty for childhood-prediabetes |
| CN108362804B (zh) * | 2018-02-27 | 2019-01-29 | 山东英盛生物技术有限公司 | 一种检测血液样品中dha含量的方法及试剂盒 |
| CN109507337B (zh) * | 2018-12-29 | 2022-02-22 | 上海交通大学医学院附属新华医院 | 一种基于血尿中代谢产物预测甘地胶囊治疗糖尿病肾病机制的新方法 |
| CN111443143B (zh) * | 2020-04-30 | 2022-04-29 | 宁波市产品食品质量检验研究院(宁波市纤维检验所) | 一种快速测定乳粉中胆固醇含量的方法 |
| CN114216851A (zh) * | 2020-11-27 | 2022-03-22 | 四川大学华西医院 | 一种基于表面增强拉曼光谱技术的急性胰腺炎评估装置 |
| KR102583808B1 (ko) * | 2021-03-05 | 2023-09-26 | 경희대학교 산학협력단 | 눈물을 이용한 당뇨병의 진단 방법 및 키트 |
| CN119534671A (zh) * | 2021-03-08 | 2025-02-28 | 江成鸿 | 组合物在制备诊断婴幼儿血管瘤和/或监测其进展及预后的药物中的应用 |
| CN114324662B (zh) * | 2021-12-30 | 2022-09-16 | 中南大学 | 用于诊断或预防糖尿病的血清生物标志物的应用 |
| CN114965753A (zh) * | 2022-05-13 | 2022-08-30 | 重庆医科大学附属第一医院 | 一种lgals3bp蛋白丰度检测试剂在制备妊娠期糖尿病泪液诊断试剂中的应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4540884A (en) | 1982-12-29 | 1985-09-10 | Finnigan Corporation | Method of mass analyzing a sample by use of a quadrupole ion trap |
| AU590883B2 (en) * | 1985-05-28 | 1989-11-23 | Nippon Kayaku Kabushiki Kaisha | Method of quantitative assay for 1,5-anhydroglucitol |
| JP2540349B2 (ja) * | 1988-01-18 | 1996-10-02 | 日本化薬株式会社 | 腎性糖尿検査方法 |
| DE69025922T2 (de) | 1989-11-30 | 1996-10-02 | Croda Int Plc | Verwendung von nervonsäure und langkettiger fettsäuren zur behandlung demyelinisierender erkrankungen |
| DE4242794A1 (en) * | 1991-12-18 | 1993-06-24 | Nitto Boseki Co Ltd | Quantitative automated determn. of 1,5-anhydro:glucitol - using pyranose oxidase from Basidiomycetes fungi no.52 |
| US5624804A (en) * | 1991-12-20 | 1997-04-29 | The Rockefeller University | Immunochemical detection of In vivo advanced glycosylation end products |
| US5397894A (en) | 1993-05-28 | 1995-03-14 | Varian Associates, Inc. | Method of high mass resolution scanning of an ion trap mass spectrometer |
| JPH0870893A (ja) * | 1994-09-02 | 1996-03-19 | Nippon Kayaku Co Ltd | 犬の糖尿病診断法、１，５−アンヒドログルシトールの定量法及びキット |
| JP3579549B2 (ja) * | 1995-10-24 | 2004-10-20 | 株式会社トクヤマ | 糖尿病または糖尿病合併症用マーカーとしての使用 |
| KR19990007908A (ko) * | 1996-02-20 | 1999-01-25 | 히라다다다시 | 1,5-안히드로글루시톨의 정량법 |
| US5965449A (en) * | 1996-07-03 | 1999-10-12 | Forbes Medi-Tech, Inc. | Method of assessing risk for cardiovascular disease and other disorders and phytosterol-based compositions useful in preventing and treating cardiovascular disease and other disorders |
| US5871949A (en) * | 1996-12-04 | 1999-02-16 | Daiichi Pure Chemicals Co., Ltd. | Method of quantitative assay for 1,5-anhydroglucitol and reagent for quantitative assay |
| JP3129250B2 (ja) * | 1997-09-10 | 2001-01-29 | 株式会社ミルス生命科学研究所 | 尿の化学分析方法 |
| CA2291912A1 (en) * | 1998-12-11 | 2000-06-11 | Kyowa Medex Co., Ltd. | Method and reagent for quantitative determination of 1,5-anhydroglucitol |
| WO2000065366A1 (en) * | 1999-04-22 | 2000-11-02 | Lipomed, Inc. | Nmr-method for determining the risk of developing type 2 diabetes |
| US6140067A (en) * | 1999-04-30 | 2000-10-31 | Mitokor | Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus |
| JP2001330599A (ja) * | 2000-05-24 | 2001-11-30 | Shimazu S D Kk | Ｇｃ／ｍｓによる代謝異常スクリーニング診断装置 |
| US20020068310A1 (en) * | 2000-10-11 | 2002-06-06 | Mihoko Sasaki | Method and reagant for quantitative determination of 1,5-anhydroglucitol |
| ES2173049B1 (es) * | 2001-03-28 | 2004-01-16 | Oleoyl Estrone Developments S | Monoester de acido graso y estrogeno como agente antidiabetico e hipolipemiante. |
| ATE386986T1 (de) * | 2001-07-06 | 2008-03-15 | Lipomics Technologies Inc | Erzeugen, betrachten, interpretieren und verwenden einer quantitativen datenbank von metaboliten |
| WO2003027296A1 (en) * | 2001-09-20 | 2003-04-03 | Plantech Research Institute | GENES PARTICIPATING IN THE SYNTHESIS OF FATTY ACID HAVING trans-11-, cis-13- CONDJUGATED DOUBLE BOND AND UTILIZATION THEREOF |
| EP1438420B1 (en) * | 2001-09-24 | 2009-09-16 | Lipomics Technologies, Inc. | Methods of using quantitative lipid metabolome data |
| US7196323B2 (en) | 2002-02-28 | 2007-03-27 | Metanomics Gmbh & Co. Kgaa | Mass spectrometry method for analyzing mixtures of substances |
| US20040024065A1 (en) * | 2002-03-11 | 2004-02-05 | Watkins Steven M. | Novel metabolic targets and markers |
| US20040132819A1 (en) * | 2002-08-06 | 2004-07-08 | Nancy Auestad | Appetite control method |
| JP2004097134A (ja) * | 2002-09-11 | 2004-04-02 | Univ Hiroshima | 鎖長延長酵素による長鎖脂肪酸の合成法 |
| JP2007523849A (ja) * | 2003-05-31 | 2007-08-23 | フォーブス メディ−テック インコーポレーテッド | １種以上のフィトステロール及び／又はフィトスタノール、及びグルコマンナンを含む組成物、及びｉｉ型糖尿病を有する又は有さない個体の脂質疾患の治療における該組成物の使用。 |
| US7648825B2 (en) * | 2003-06-20 | 2010-01-19 | University Of Florida Research Foundation, Inc. | Biomarkers for differentiating between type 1 and type 2 diabetes |
| JP4066259B2 (ja) * | 2003-09-11 | 2008-03-26 | 財団法人大阪産業振興機構 | 軟体動物由来廃棄物の処理方法 |
| EP1733345A4 (en) * | 2004-02-17 | 2010-11-24 | Bodybio Inc | NETWORK AND METHODS FOR INTEGRATING RESULTS OF INDIVIDUALIZED CLINICAL TESTS AND NUTRITIONAL TREATMENT |
| US20050202521A1 (en) * | 2004-03-10 | 2005-09-15 | Albert Crum | Methods of assessing the need for and the effectiveness of therapy with antioxidants |
| ATE476659T1 (de) * | 2004-06-09 | 2010-08-15 | Becton Dickinson Co | Sensor für mehrere analyte |
| CN101035594B (zh) * | 2004-08-09 | 2013-10-23 | 酶学技术有限公司 | 用于糖尿病患者的食品 |
| WO2006073195A1 (ja) * | 2005-01-07 | 2006-07-13 | Biomarker Science Co., Ltd | 糖尿病の予知・診断方法および糖尿病予知・診断用キット |
| CA2647122A1 (en) | 2006-03-24 | 2007-10-04 | Metanomics Gmbh | Means and method for diagnosing diabetes |
| EP2164977B1 (en) * | 2007-07-17 | 2013-10-30 | Metabolon, Inc. | Biomarkers for pre-diabetes and methods using the same |
-
2007
- 2007-03-21 CA CA002647122A patent/CA2647122A1/en not_active Abandoned
- 2007-03-21 DE DE602007011592T patent/DE602007011592D1/de active Active
- 2007-03-21 EP EP07727167A patent/EP2005189B1/en not_active Not-in-force
- 2007-03-21 EP EP07727168A patent/EP2008108B1/en not_active Not-in-force
- 2007-03-21 CN CN2007800162752A patent/CN101438168B/zh not_active Expired - Fee Related
- 2007-03-21 DE DE602007011588T patent/DE602007011588D1/de active Active
- 2007-03-21 US US12/293,598 patent/US8216848B2/en not_active Expired - Fee Related
- 2007-03-21 EP EP10196430.2A patent/EP2330423B1/en not_active Not-in-force
- 2007-03-21 EP EP10196650.5A patent/EP2339346B1/en not_active Not-in-force
- 2007-03-21 ES ES10196643.0T patent/ES2522815T3/es active Active
- 2007-03-21 EP EP10196643.0A patent/EP2369346B1/en not_active Not-in-force
- 2007-03-21 AT AT07727167T patent/ATE493660T1/de active
- 2007-03-21 ES ES10196649.7T patent/ES2522816T3/es active Active
- 2007-03-21 CA CA002647197A patent/CA2647197A1/en not_active Abandoned
- 2007-03-21 AT AT07727168T patent/ATE493661T1/de active
- 2007-03-21 JP JP2009500866A patent/JP5199994B2/ja not_active Expired - Fee Related
- 2007-03-21 WO PCT/EP2007/052692 patent/WO2007110358A2/en not_active Ceased
- 2007-03-21 US US12/293,587 patent/US8216847B2/en not_active Expired - Fee Related
- 2007-03-21 JP JP2009500865A patent/JP5167239B2/ja not_active Expired - Fee Related
- 2007-03-21 ES ES10196650.5T patent/ES2522818T3/es active Active
- 2007-03-21 ES ES10196430.2T patent/ES2525345T3/es active Active
- 2007-03-21 WO PCT/EP2007/052691 patent/WO2007110357A2/en not_active Ceased
- 2007-03-21 EP EP10196649.7A patent/EP2336782B1/en not_active Not-in-force
- 2007-03-23 AR ARP070101230A patent/AR060121A1/es not_active Application Discontinuation
- 2007-03-23 AR ARP070101229A patent/AR060120A1/es unknown
-
2012
- 2012-10-16 JP JP2012228718A patent/JP2013057672A/ja not_active Ceased
- 2012-11-09 JP JP2012247306A patent/JP5579819B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060120A1 (es) | Medio y metodo para diagnosticar la diabetes | |
| ES2506116T3 (es) | Nuevo biomarcador para diagnóstico, predicción y/o pronóstico de septicemia y usos del mismo | |
| EP2804001A3 (en) | Methods for diagnosing prostate carcinomas | |
| Wadhawan et al. | Hepatic venous pressure gradient in cirrhosis: correlation with the size of varices, bleeding, ascites, and child's status | |
| Bastarache et al. | Validation of a multiplex electrochemiluminescent immunoassay platform in human and mouse samples | |
| NZ593514A (en) | p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer | |
| MX2009000697A (es) | Sistema y metodo para medir un analito en una muestra. | |
| WO2010002911A3 (en) | Methods and materials for monitoring myeloma using quantitative mass spetrometry | |
| BR112013003391B8 (pt) | Método para diagnosticar câncer pancreático em um indivíduo | |
| BR112012019542A2 (pt) | "método para avaliar o estado renal em um indivíduo, medição de um ou mais biomarcadores, e, kit" | |
| WO2009152607A8 (en) | Methods and kits for diagnosing neurodegenerative disease | |
| BR112014006741A2 (pt) | método para monitorização, diagnóstico e/ou prognóstico de lesão renal aguda no estágio inicial | |
| WO2009140411A3 (en) | Computer-implemented methods, carrier media, and systems for selecting polarization settings for an inspection system | |
| NZ619883A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| NZ592365A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| NZ625423A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| WO2009088816A3 (en) | Systems and methods for well data analysis | |
| Anglicheau et al. | Discovery and validation of a molecular signature for the noninvasive diagnosis of human renal allograft fibrosis | |
| Ayers et al. | Procoagulant and platelet-derived microvesicle absolute counts determined by flow cytometry correlates with a measurement of their functional capacity | |
| Salgado et al. | Cystatin C, kidney function, and cardiovascular risk factors in primary hypertension | |
| BR112013000869A2 (pt) | método para diagnóstico de câncer de próstata (pca) com uma sensibilidade desejada em um sujeito; método para monitorar a progressão do câncer de próstata (pca) em um sujeito; método para avaliar se um sujeito tem que ser submetido a uma biópsia de próstata; kit compreendendo um primeiro componente e, opcionalmente, um segundo componente e uso de um kit | |
| WO2009006347A3 (en) | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes | |
| WO2010051544A3 (en) | Rapid homogeneous diagnostic testing platform based on lanthanide fluorescent resonance energy transfer | |
| Javanmardi et al. | Diagnostic value of cystatin C for diagnosis of early renal damages in type 2 diabetic mellitus patients: The first experience in Iran | |
| Wu et al. | Albuminuria, proteinuria, and urinary albumin to protein ratio in chronic kidney disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |